City of Hope
Division of Clinical Cancer Genetics
Publications

Index

2014

1. Antoniou AC, Casadei S, Heikkinen T, Weitzel, JN, …et al. **Inherited loss-of-function mutations in PALB2 and breast cancer risk.** New Engl J Med. 2014 [In Press].

2. Gronwald J, Robidoux A, Kim-Sing C, Weitzel, JN, …et al. (2014) **Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.** Breast Cancer Res Treat. 146(2):421-427.

3. Hernandez JE, Llacuachaqui M, Palacio G, …Weitzel, JN, Narod, S. (2014) **Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellin, Colombia.** Hered Cancer Clin Pract. 12(1):11.

4. Nelson DE, Faupel-Badger J, Phillips S, …Weitzel, JN. (2014) **Future directions for postdoctoral training in cancer prevention: insights from a panel of experts.** Cancer Epidemiol Biomar. 23(4):679-683.

5. Osorio A, Milne RL, Vaclová T, Pita G, Weeman K, CIMBA. **DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.** PLoS Genetics. 2014;10(4):e1004256.

6. Thompson BA, Spurdle AB, Plazzer JP, ...Espenschied, et al. **Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.** Nat Genet. 2014;46(2):107-115.

7. Wain KE, …Weitzel, JN, …Lindor N. (2014 ePub ahead of print] **Appreciating the broad clinical features of SMAD4 mutation carriers: a multi-center chart review.** Genet Med. PMCID: PMC Journal - In Process.

8. Wood M, Kadlubek P, Pham T, Weitzel, JN, …et al. (2014) **Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology quality oncology practice initiative.** J Clin Oncol. 32(8):824-829.

2013

1. Ashing-Giwa K, Rosales M, Lai L, Weitzel JN. (2013) **Depressive Symptoms in Latina Breast Cancer Survivors.** Psycho-oncology, 22(4):845-853.

City of Hope
Division of Clinical Cancer Genetics
Publications

2. Bojesen SE, Pooley KA, Michailidou K, Jonathan Beesley, Pickett HA, Shen HC, Smart CE, Mai PL, Lawrenson K,…Weitzel, JN, et al. (2013) **Multiple independent TERT variants associated with telomere length and risks of breast and ovarian cancer.** Nature Genetics, 45(4):371-384. PMCID: PMC3670748

3. Couch FJ, Wang X, McGuffog L, …Weitzel, JN, …et al. (2013) **Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.** PLOS Genetics. 9(3):e1003212. PMCID: PMC3609646.

4. Culver JO, Brinkerhoff CD, Clague J, K. Y, Singh K, Sand SR, Weitzel JN. (2013) **Variants of Uncertain Significance in BRCA Testing: Evaluation of Surgical Decisions, Risk Perception, and Cancer Distress.** Clin Genet. 84(5):464-472. PMCID: PMC3751990.

5. Finch A, Valentini A, Greenblatt E, …Weitzel, JN, et al. (2013) **Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation.** Fertil Steril. 99(6):1724-1728.

6. Gaudet M, Kuchenbaecker K, Vijai J,…Weitzel JN, et al. (2013) **Identification of a BRCA2-specific Modifier Locus at 6p24 Related to Breast Cancer Risk.** PLoS Genet. 9(3):e1003173. PMCID: PMC3609647.

7. Laitman Y, Feng B-J, Zamir IM, Weitzel JN, Duncan P, Port D, Thirthagiri E, Teo SH, Evans DG, et al. (2013) **Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations.** Europ. J. Hum. Genet. 21(2):212-216. PMCID: PMC3548269.

8. Ortiz JA, Weitzel JN. (2013) **Evidence of BRCA Gene Mutations Among Hispanics Shows Clinical Utility.** The UCLA Undergraduate Science Journal. 26:50-57.

9. Rebbeck T, Mitra N, Wan F, …Weitzel, JN, et al. (2013 In Press) **Mutation-specific Cancer Risks Estimated from 31,481 Female Carriers of BRCA1 or BRCA2 Mutations.** Cancer Res. PMCID: PMC Journal - In Process.

10. Santos EMM, Edwards QT, Floria-Santos M, Rogatto SR, Achatz MIW, MacDonald DJ. (2013) **Integration of Genomics in Cancer Care.** Journal of Nursing Scholarship. 45 (1):43-51

11. Segev Y, Iqbal J, Lubinski J, …Weitzel, JN, et al. (2013) **The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study.** Gynecol Oncol. 130(1):127-131.

12. Silva TB, Macdonald DJ, et al. (2013) **Perception of cancer causes and risk, family history and preventive behaviors of users in oncogenetic counseling.** Rev Esc Enferm USP. 47: p. 377-384.

13. Sorrell AD, Espenschied C, Culver J, Weitzel J. (2013) **Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome: Current Status of Clinical Applications and Future Directions.** Mol Diagn Ther.17(1):31-47. PMCID: PMC3627545.

14. Southey MC, Park DJ, Nguyen-Dumont T, …Weitzel, JN, et al. (2013) **COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration.** Breast Cancer Research. 15(3):402. PMCID: PMC3706918.

15. Valentini A, Lubinski J, Byrski T, …Weitzel, JN, et al. (2013) **The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation.** Breast Cancer Res Treat 142 (1):177-185. PMCID: PMC Journal - In Process.

City of Hope
Division of Clinical Cancer Genetics
Publications

16. Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, Jungbluth C, Cina C, Duncan P, et al. (2013) **Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network.** J Clin Oncol. 31(2):210-216. PMCID: PMC3532393

2012

1. Beamer, L., Grant, M., Espenschied, C., Blazer, K., Hampel, H., Weitzel, JN, & MacDonald, DJ (2012) **Reflex Immunohistochemistry and Microsatellite Instability Testing of Colorectal Tumors for Lynch Syndrome among US Cancer Programs and Follow-up of Abnormal Results.** J Clin Oncol, 1;30(10):1058-63

2. Blazer, KR, Christie, C., Uman, G., & Weitzel, JN (2012). **Impact of Web-based Case Conferencing on Cancer Genetics Training Outcomes for Community-based Clinicians.** J Cancer Educ, 27(2):217-225. NIHMS ID: 431334

3. Clark CC, Weitzel JN, O'Connor TR (2012) **Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models.** Molecular Cancer Therapeutics 11 (9):1948-1958. PMCID: PMC3551628.

4. Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y,…Weitzel, JN,…Neuhausen, SL (2012) **A non-synonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.** Cancer Epidem Biomar, 21:1362-1370. PMCID: PMC3415567.

5. Espenschied, CR, MacDonald, DJ, Culver, JO, Sand, S., Hurley, K., Banks, K. C., Weitzel, JN, & Blazer, KR (2012). **Closing the Loop: Action research in a multimodal hereditary cancer patient conference is an effective tool to assess and address patient needs.** Journal of Cancer Education, 27(3):467-477. PMCID: PMC3540105.

6. Finkelman, B.S., Rubinstein, W.S., Friedman, S., Friebel, T. M., Dubitsky, S., Schonberger, N., Shoretz, R., Singer, C. F., Blum, J. L., Tung, N., Olopade, O.I., Weitzel, JN, et al. (2012) **Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers.** J Clin Oncol, 30 (12):1321-1328. PMCID: PMC3341145.

7. Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N,…Weitzel, JN, et al. (2012) **Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers?** Cancer Epidem Biomar, 1(7):1089-1096. PMCID: PMC3593267.

8. Liu, J., Cristea, M. C., Frankel, P., Neuhausen, SL, Steele, L., Engelstaedter, V., Matulonis, U., Sand, S., Tung N., Garber, JE, & Weitzel, JN (2012). **Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): genotype and survival.** Cancer Genet, 205, 34-41

9. MacDonald DJ, Deri J, Ricker C, Perez MA, Ogaz R, Feldman N, Viveros LA, Paz B, Weitzel JN, Blazer, KR. (2012) **Closing the Loop: An interactive action-research conference format for delivering updated medical information while eliciting Latina patient/family experiences and psychosocial needs post-genetic cancer risk assessment.** Familial Cancer. 11(3):449-445 PMCID: PMC3620038.

10. Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong L, Wyss O, Locke L, Means V, et al. (2012) **Li-Fraumeni syndrome: Report of a clinical research workshop and creation of a research consortium. Cancer Genetics,** 205(10):479-487. PMCID: PMC3593717

11. Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, JN, Balmana, J., et al. (2012). **Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.** Breast Cancer Research and Treatment. 133(3):1125-1130. PMCID: PMC Journal - In Process

12. Newhauser, W. D., Scheurer, M. E., Faupel-Badger, J. M., Clague, J., Weitzel, J., & Woods, K. V. (2012). **The Future Workforce in Cancer Prevention: Advancing Discovery, Research, and Technology.** Journal of Cancer Education, 27 Suppl 2:S128-35.

13. Pilarski R, Patel DA, Weitzel JN, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, et al. (2012) **The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer.** PLoS One, 7(5):e37891. PMCID: PMC3360659

14. Ratner, E. S., …Weitzel, JN, Neuhausen, SL, Schwartz, P. E., Slack, FJ, Santin, A. D., Weidhaas, J. B. (2012). **A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.** Oncogene, 31(42):4559-4566. PMCID: PMC3342446.

15. Rodriguez, A. O., Llacuachaqui, M., Pardo, G. G., Royer, R., Larson, G., Weitzel, JN, & Narod, S. A. (2012). **BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia.** Gynecol Oncol., 124, 236-243.

16. Sorrell A, Espenschied C, Wang W, Weitzel JN, Chu S, Parker P, Saldivar S, Bhatia R. (2012) **Hereditary leukemia due to rare RUNX1c splice variant (L472X) presents with eczematous phenotype.** Int J Clin Med, 3:607-613. PMCID: PMC Journal - In Process

2011

1. Blazer, KR, MacDonald, DJ, Culver, JO, Huizenga, CR, Morgan, RJ, Uman, GC, & Weitzel, JN (2011). **Personalized cancer genetics training for personalized medicine: Improving community-based healthcare through a genetically literate workforce**. Genet Med. 13(9), 832-840.

2. Brown, S. M., Culver, JO, Osann, K. E., MacDonald, DJ, Sand, S., Thornton, A. A., ...Weitzel, JN (2011). **Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates.** Patient Educ Couns, 83(1), 92-98.

3. Clague J, Wilhoite G, Adamson A, Bailis A, Weitzel JN, Neuhausen SL. (2011). **RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.** PLoS One, 6(9), e25632.

4. Culver, JO, MacDonald, DJ, Thornton, A. A., Sand, S. S., Grant, M., Bowen, DJ, …Weitzel, JN (2011). **Development and evaluation of a decision aid for BRCA carriers with breast cancer.** J Gen Couns , 20(3), 294-307.

5. Im, K. M., Kirchhoff, T., Wang, X., Green, T., Chow, C. Y., Vijai, J., ...Weitzel, JN, et al. (2011) **Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.** Hum Genet, 130(5), 685-699.

City of Hope
Division of Clinical Cancer Genetics
Publications

6. Kempers, M. J., Kuiper, R. P., Ockeloen, C. W., Chappuis, P. O., Hutter, P., Rahner, N.,…Culver, JO, et al. (2011). **Risk of colorectal and endometrial cancers in epcam deletion-positive Lynch Syndrome: A cohort study.** Lancet Oncol, 12 (1):49-55.

7. Lagos-Jaramillo, V. I., Press, M. F., Ricker, C. N., Dubeau, L., Mai, P. L., & Weitzel, JN (2011). **Pathological characteristics of BRCA-associated breast cancers in Hispanics.** Breast Cancer Res Treat, 130(1), 281-289.

8. MacDonald, DJ (2011). **Germline Mutations in Cancer Susceptibility Genes: An Overview for Nurses.** Semin Oncol Nurs, 27(1), 21-33.

9. Miller-Samuel, S., McDonald, DJ, Weitzel, JN, Santiago, F., Martino, M. A., Namey, T., et al. (2011). **Variants of uncertain significance in breast cancer-related genes: real-world implications for a clinical conundrum. Part one: clinical genetics recommendations.** Semin Oncol, 38(4), 469-480.

10. Mulligan, A. M., Couch, FJ, Barrowdale, D., Domchek, S. M., Eccles, D., Nevanlinna, H., …Weitzel, JN, et al. (2011). **Common breast cancer susceptibility alleles are associated with tumor subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.** Breast Cancer Res, 13(6), R110.

11. Neuhausen, SL, Brummel, S., Ding, Y., Steele, L., Nathanson, K., Domchek, S. M., …Weitzel, JN, et al. (2011). **Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk Among BRCA1 and BRCA2 Carriers.** Cancer Epidem Biomar, 2011; 8(20): 1690-1702.

12. Rebbeck, T., Mitra, N., Domchek, S. M., Wan, F., Friebel, T. M., Tran, T. V.,…Weitzel, JN, et al. (2011) **Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes.** Cancer Res. 71(17), 5792-5805.

13. Sorrell, A. D., Lee, S., Stolle, C., Ellenhorn, J., Grix, A., Kaelin, W. G., Jr., & Weitzel, JN (2011). **Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.** Clin Genet, 79(6), 539-545.

14. Spurdle, M., Marquart, L., McGuffog, L., Healey, S., Sinilnikova, O. M., Wan, F., …Weitzel, J.N, et al. (2011). **Common genetic variation at BARD1 is not associated with Breast cancer risk in BRCA1 or BRCA2 mutation carriers.** Cancer Epidem Biomar, 20(5), 1032-1038.

15. Weitzel, JN, Blazer, KR, MacDonald, DJ, Culver, JO, & Offit, K. (2011) **Genetics, Genomics and Cancer Risk Assessment: State of the art and future directions in the era of personalized medicine.** CA-Cancer J Clin, 61(5), 327-359.

2010

1. Allain, D., Baker, M., Blazer, KR, Cohen, S., Copeland, K., Djurdjinovic, L., et al. (2010). **Evolving models of cancer risk genetic counseling.** Perspectives in Genetic Counseling, 32(1), 14-17. Retrieved from http://www.nsgc.org/source/security/member-logon.cfm?section= home.

2. Antoniou, AC, Wang, X, Fredericksen, ZS, McGuffog, L, Tarrell, R, Sinilnikova, OM, ...Weitzel, JN, et al. (2010) **A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.** Nat Genet, 42(10), 885-892.

City of Hope
Division of Clinical Cancer Genetics
Publications

3. Antoniou, AC, Beesley, J, McGuffog, L, Sinilnikova, OM, Healey, S, Neuhausen, SL, …Weitzel, JN, et al. (2010). **Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Implications for risk prediction.** Cancer Res, 70(23), 9742-9754.

4. Audeh, MW, Carmichael, J, Penson, RT, Friedlander, M, Powell, B, ...Weitzel, JN, et al. (2010) **Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial.** Lancet, 376(9737), 211-213.

5. Blazer, KR, Clague, J., Collie, C. L., Ciadella-Kam, L. A., Kuratani, D. G., Laird, SL, et al. (2010). **"Future directions in cancer prevention and control: Workforce implications for training, practice, and policy" Symposium, October 17 to 18, 2009, the University of Texas M. D. Anderson Cancer Center.** Cancer Epidem Biomar, 19(6), 1655-1660.

6. Daly, MB, Axilbund, JE, Buys, S, Crawford, B, Farrell, CD, …Weitzel, JN (2010) **Genetic/familial high-risk assessment: Breast and ovarian.** J Natl Compr Canc Netw, 8(5), 562-594.

7. Domchek, SM, Friebel, TM, Garber, JE, Isaacs, C, Matloff, E, Eeles, R, ...Weitzel, JN, et al. (2010) **Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.** Breast Cancer Res Treat, 124(1), 195-203.

8. Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, HT, Isaacs, C., …Weitzel, JN, et al. (2010). **Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.** JAMA, 304(9), 967-975.

9. Gaudet, M. M., Kirchhoff, T., Green, T., Vijai, J., Korn, J. M., Guiducci, C., ...Weitzel, JN, et al. (2010). **Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.** PLoS Genet, 6(10), e1001183.

10. Huizenga, CR, Lowstuter, K. J., Banks, K. C., Lagos, V. I., Vandergon, V. O., & Weitzel, JN (2010). **Evolving perspectives on genetic discrimination in health insurance among health care providers.** Fam Cancer, 9, 253-260. PMCID: PMC Journal - In Process

11. Jasperson, K., Vu, T. M., Schwab, A. L., Neklason, D. W., Rodriguez-Bigas, M. A., Burt, R. W., & Weitzel, JN (2010). **Evaluating Lynch Syndrome in very early onset colorectal cancer probands without apparent polyposis.** Fam Cancer, 9(2), 99-107. PMCID: PMC3620042.

12. MacDonald, DJ (2010). **Establishing a cancer genetics service.** In H. Kuerer (Ed.), Kuerer's breast surgical oncology. New York, NY: McGraw-Hill.

13. MacDonald, DJ, Blazer, KR, & Weitzel, JN (2010). **Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: The power of partnership.** J Natl Compr Canc Netw, 8(5), 615-624.

14. MacDonald, DJ, Sarna, L, Weitzel, JN, Ferrell, B (2010) **Women's perceptions of the personal and family impact of genetic cancer risk assessment: Focus group findings.** J Genet Couns, 19(2), 148-160.

15. Robson, M. E., Storm, C. D., Weitzel, JN, Wollins, D. S., & Offit, K. (2010). **American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility.** J Clin Oncol, 28(5), 893-901.

16. Stadler, Z. K., Thom, P., Robson, M. E., Weitzel, JN, Kauff, N. D., Hurley, K. E., et al. (2010). **Genome-wide association studies of cancer.** J Clin Oncol, 28(27), 4255-4267.

City of Hope
Division of Clinical Cancer Genetics
Publications

17. Tutt, A., Robson, M., Garber, JE, Domchek, S. M., Audeh, MW, Weitzel, JN, et al. (2010). **Oral poly (adp-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial.** Lancet, 376(9737), 211-213.

2009

1. Gonzalez KDF, Weitzel JN, Sommer SS. (2009) **Reply to J. Tinat.** J Clin Oncol. 27(26): E110.

2. Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., ...Weitzel, JN (2009). **Beyond Li –Fraumeni Syndrome: Clinical characteristics of families with p53 germline mutations.** J Clin Oncol, 27(8), 1250-1256.

3. McKinnon, W., Banks, K. C., Skelly, J., Kohlmann, W., Bennett, R., Shannon, K., ...Weitzel, JN, et al. (2009). **Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals.** Fam Cancer, 8(4), 363-369.

4. Neuhausen, SL, Brummel, S., Ding, Y. C., Singer, C. F., Pfeiler, G., Lynch, HT, ...Weitzel, JN, et al. (2009). **Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.** Breast Cancer Res, 11(5), R76.

5. Pal, S. K., Blazer, KR, Weitzel, JN, & Somlo, G. (2009). **An association between invasive breast cancer and familial idiopathic hyperparathyroidism: A case series and review of the literature.** Breast Cancer Res Treat, 115: 1-5.

6. Rebbeck, T. R., Mitra, N., Domchek, S. M., Wan, F., Chuai, S., Friebel, T. M., ...Weitzel, JN, et al. (2009). **Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.** Cancer Res, 69(14), 5801-5810.

7. Torres, D., Rashid, M. U., Seidel-Renkert, A., Weitzel, JN, Briceno, I., & Hamann, U. (2009). **Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics.** Breast Cancer Res Treat, 117(3), 679-681.

2008

1. Antoniou, AC, Spurdle, A. B., Sinilnikova, O. M., Healey, S., Pooley, K. A., Schmutzler, R. K., ...Weitzel, JN, et al. (2008). **Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.** Am J Hum Genet, 82(4), 937-948.

2. Jasperson, K. W., Blazer, KR, Lowstuter, K. J., & Weitzel, JN (2008). **Working through a diagnostic challenge: Colonic polyposis, Amsterdam criteria, and a mismatch repair mutation.** Fam Cancer, 7(4), 281-285.

3. Lagos, VI, Perez, MA, Ricker, CN, Blazer, K R, Santiago, NM, Feldman, N, ...Weitzel, JN. (2008) **Social cognitive aspects of underserved Latinas preparing to undergo genetic risk assessment for hereditary breast and ovarian cancer.** Psycho-oncol, 17(8), 774-782.

4. Lowstuter, K. J., Sand, S., Blazer, KR, MacDonald, DJ, Banks, K. C., Lee, C. A., et al. (2008). **Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians.** Genet Med, 10(9), 691-698.

City of Hope
Division of Clinical Cancer Genetics
Publications

5. MacDonald, DJ, Sarna, L., Giger, JN, Bastani, R., van Servellen, G., & Weitzel, JN (2008). **Comparison of Latina and non-Latina white women's beliefs about communicating genetic cancer risk to relatives.** J Health Commun, 13(5), 465-479.

6. Mai, P. L., Lagos, V. I., Palomares, MR, & Weitzel, JN (2008). **Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment.** Ann Surg Oncol, 15(12), 3415-3421.

7. Maradiegue, A., Jasperson, K. W., Edwards, Q. T., Lowstuter, K. J., & Weitzel, JN (2008). **Scoping the family history: Assessment of Lynch Sndrome (hereditary nonpolyposis colorectal cancer) in primary care settings—A primer for nurse practitioners.** J Am Acad Nurse Pract, 20(2), 76-84.

8. Metcalfe, K. A., Lubinski, J., Ghadirian, P., Lynch, H., Kim-Sing, C., Friedman, E., ...Weitzel, JN, et al. (2008). **Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The Hereditary Breast Cancer Clinical Study Group.** J Clin Oncol, 26(7), 1093-1097.

9. West, J. G., Weitzel, JN, Tao, M. L., Carpenter, M., West, JE, & Fanning, C. (2008). **BRCA1/2 mutations and the risk of angiosarcoma following breast cancer treatment.** Clin Breast Cancer, 8(6), 533-537.

2007

1. Antoniou, AC, Sinilnikova, OM, Simard, J, Leone, M, Dumont, M, Neuhausen, SL, ...Weitzel, JN, et al. (2007) **RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: Results from a combined analysis of 19 studies.** Am J Hum Genet, 81(6), 1186-1200.

2. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, MacDonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH. (2007) **Breast cancer risk reduction.** J Natl Compr Canc Netw. 5(8): 676-701.

3. Couch, FJ, Sinilnikova, O, Vierkant, RA, Pankratz, VS, Fredericksen, ZS, ...Weitzel, JN, et al. (2007) **AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A CIMBA study.** Cancer Epidemiol Biomarkers Prev, 16(7), 1416-1421.

4. Culver, JO, Lowstuter, K. J., & Bowling, L. G. (2007). **Assessing breast cancer risk and BRCA1/2 carrier probability.** Breast Dis, 27, 5-20.

5. Edwards, Q. T., Seibert, D., Maradiegue, A., MacDonald, DJ, Jasperson, K. W., Lowstuter, K. J., & Weitzel, JN (2007). **Breast cancer and the family tree: An issue for all practice settings.** Adv Nurse Pract, 15(5), 34-41.

6. Friebel, T. M., Domchek, S. M., Neuhausen, SL, Wagner, T., Evans, D. G., Isaacs, C., ...Weitzel, JN, et al. (2007). **Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.** Clin Breast Cancer, 7(11), 875-882.

7. Kotsopoulos, J., Lubinski, J., Lynch, HT, Klijn, J., Ghadirian, P., Neuhausen, SL, ...Weitzel, JN, et al. (2007). **Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.** Breast Cancer Res Treat, 105(2), 221-228.

City of Hope
Division of Clinical Cancer Genetics
Publications

8. MacDonald, DJ, Sarna, L, van Servellen, G, Bastani, R, Giger, JN, Weitzel, JN. (2007) **Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment.** Genet Med, 9(5), 275-282.

9. Parmigiani, G, Chen, S, Iversen, ES, Kligner, TM, Finkelstein, D, Anton-Culver, H, ...Weitzel, JN, et al. (2007). **Validity of models for prediction of BRCA1 and BRCA2 mutations.** Ann Intern Med, 147, No. 7, 441-450.

10. Ricker, CN, Hiyama, S, Fuentes, S, Feldman, N, Kumar, V, ...Weitzel, JN (2007) **Beliefs and interest in cancer risk in an underserved Latino cohort.** Prev Med, 44(3), 241-245.

11. Weitzel, JN, Buys, SS, Sherman, WH, Daniels, AM, Ursin, G, ...MacDonald, DJ, Blazer, KR, et al. (2007) **Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.** Clin Cancer Res, 13(2), 654-658.

12. Weitzel, JN, Lagos, V. I., Cullinane, C. A., Gambol, P. J., Culver, JO, Blazer, KR, Palomares, MR, Lowstuter, K. J., & MacDonald, DJ (2007). **Limited family structure and BRCA gene mutation status in single cases of breast cancer.** JAMA, 297(23), 2587-2595.

13. Weitzel, JN, Lagos, VI, Herzog, JS, Judkins, T, Hendrickson, B, Ho, JS, ...Blazer, KR, et al. (2007) **Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families.** Cancer Epidem Biomar, 16(8), 1615-1620.

2006

1. Blazer, KR, MacDonald, DJ, Justus, K. A., Grant, M., Azen, S. P., Chamberlain, R. M., et al. (2006). **Creating tomorrow's leaders in cancer prevention: A novel interdisciplinary career development program in cancer genetics research.** J Cancer Educ, 21(4), 216-222.

2. Daly, MB, Axilbund, JE, Bryant, E, Buys, S, Eng, C, …Weitzel, JN (2006). **Genetic/familial high-risk assessment: Breast and ovarian.** J Natl Compr Canc Netw, 4(2), 156-176.

3. Finch, A., Beiner, M., Lubinski, J., Lynch, HT, Moller, P., Rosen, B., ...Weitzel, JN, et al. (2006). **Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation.** JAMA, 296(2), 185-192.

4. Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, MB, ...Weitzel, JN, et al. (2006). **Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update.** Int J Cancer, 118(9), 2281-2284.

5. Guillem, J. G., Wood, W. C., Moley, J. F., Berchuck, A., Karlan, B. Y., Mutch, D. G., ...Weitzel, JN, et al. (2006). **ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.** J Clin Oncol, 24(28), 4642-4660.

6. Guillem, J. G., Wood, W. C., Moley, J. F., Berchuck, A., Karlan, B. Y., Mutch, D. G., ...Weitzel, JN, et al. (2006). **ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.** Ann Surg Oncol, 13(10), 1296-1321.

7. Jasperson, K. W., Lowstuter, K. J., & Weitzel, JN (2006) **Assessing the predictive accuracy of HMLH1 and HMSH2 mutation probability models.** J Genet Couns, 15(5), 339-347.

8. MacDonald, DJ, Sand, S., Kass, F., Blazer, KR, Congleton, J., Craig, J., & Weitzel, JN (2006). **The power of partnership: Extending comprehensive cancer center expertise in clinical cancer genetics to community breast care centers.** Semin Breast Dis, 9, 39-47.

9. MacDonald, DJ, Sarna, L., Uman, GC, Grant, M., & Weitzel, JN (2006). **Cancer screening and risk reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers.** Oncol Nurs Forum, 33(2), E27-35.

10. Ricker, C., Lagos, V. I., Feldman, N., Hiyama, S., Fuentes, S., Kumar, V., Gonzalez, K., Palomares, MR, Blazer, KR, Lowstuter, K. J., MacDonald, DJ, & Weitzel, JN (2006). **If we build it…will they come?--establishing a cancer genetics services clinic for an underserved predominantly Latina cohort.** J Genet Couns, 15(6), 505-514.

2005

1. Blazer, KR, MacDonald, DJ, Ricker, C, Sand, S, Uman, GC, Weitzel, JN (2005) **Outcomes from intensive training in genetic cancer risk counseling for clinicians.** Genet Med, 7(1), 40-47.

2. Cullinane, CA, Lubinski, J, Neuhausen, SL, Ghadirian, P, Lynch, HT, Isaacs, C, Weber, B, ...Weitzel, JN, et al. (2005). **The effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.** Int J Cancer, 117(6), 988-991.

3. Culver, JO, Edwards, Q. T., MacDonald, DJ, & Weitzel, JN (2005). **USPSTF guidelines will miss BRCA families due to paternal inheritance or a truncated family tree.** Ann Intern Med, 143(5), 355. Retrieved from http://www.annals.org/content/143/5/355.abstract/ reply# nnintmed_el_2247

4. Larson, G. P., Ding, Y., Cheng, L. S., Lundberg, C., Gagalang, V., Guillermo, R., ...Weitzel, JN, MacDonald, DJ, et al. (2005). **Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT.** Cancer Res, 65(3), 805-814.

5. MacDonald, DJ, Sarna, L, Uman, GC, Grant, M, & Weitzel, JN (2005) **Health beliefs of women with and without breast cancer seeking genetic cancer risk assessment.** Cancer Nurs, 28(5), 372-379.

6. Palomares, MR, Paz, IB, Weitzel, JN (2005) **Genetic cancer risk assessment in the newly diagnosed breast cancer patient is useful and possible in practice.** J Clin Oncol, 23(13), 3165-3166.

7. Weitzel, JN, Lagos, V. I., Blazer, KR, Nelson, R., Ricker, C., Herzog, J., et al. (2005). **Prevalence of BRCA mutations and founder effect in high-risk Hispanic families.** Cancer Epidem Biomar, 14, 1666-1671.

8. Weitzel, JN, Robson, M, Pasini, B, Manoukian, S, …D, Lynch, HT, et al. (2005) **A comparison of bilateral breast cancers in BRCA carriers.** Cancer Epidem Biomar, 14(6), 1534-1538.

2004

1. Blazer, KR, Grant, M., Sand, SR, MacDonald, DJ, Uman, GC, & Weitzel, JN (2004). **Effects of a cancer genetics education programme on clinicians knowledge and practice.** J Med Genet, 41(7), 518-522.

City of Hope
Division of Clinical Cancer Genetics
Publications

2. Brenner, RJ, Weitzel, JN, Hansen, N., & Boasberg, P. (2004). **Screening detected breast cancer in a man with BRCA2 mutation: Case report.** Radiology, 230(2), 553-555.

3. Jardines, L., Haffty, B. G., Doroshow, J. H., Fisher, P., & Weitzel, JN (2004). **Breast cancer overview: Risk factors, screening, genetic testing, and prevention.** In R. Pazdur, L. R. Coia, W. J. Hoskins & L. D. Wagman (Eds.), Cancer management: A multidisciplinary approach medical, surgical & radiation oncology (8th ed., pp. 165-190). Manhasset, New York: CMP Healthcare Media, Oncology Publishing Group.

4. MacDonald, DJ, & Weitzel, JN (2004) **Keeping current with risk reduction strategies for patients at hereditary cancer risk.** International Society of Nurses in Genetics Newsletter, 12(2), Pages 1-15.

5. Martinez, SL, Herzog, J., & Weitzel, JN (2004). **Loss of five amino acids in BRCA2 is associated with ovarian cancer.** J Med Genet, 41(2), e18.

6. Nedelcu, R., Blazer, KR, Schwerin, BU, Gambol, P., Mantha, P., Uman, GC, & Weitzel, JN (2004). **Genetic discrimination: The clinician perspective.** Clin Genet, 66(4), 311-317.

7. Somlo, G., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, R., Jr., ...Weitzel, JN, et al. (2004). **Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.** J Clin Oncol, 22(10), 1839-1848.

8. Weitzel, JN (2004). **Evidence for advice: Reduction in risk of breast or ovarian cancer after salpingo-oophorectomy in carriers of BRCA1 or BRCA2 mutations.** Breast Diseases: A Year Book Quarterly, 14(4), 354-356.